Ourania Rosella
Overview
Explore the profile of Ourania Rosella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choy M, Li Wai Suen C, Con D, Boyd K, Pena R, Burrell K, et al.
Lancet Gastroenterol Hepatol
. 2024 Sep;
9(11):981-996.
PMID: 39236736
Background: The optimal dosing strategy for infliximab in steroid-refractory acute severe ulcerative colitis (ASUC) is unknown. We compared intensified and standard dose infliximab rescue strategies and explored maintenance therapies following...
2.
Prentice R, Flanagan E, Wright E, Gibson P, Rosella S, Rosella O, et al.
Clin Gastroenterol Hepatol
. 2024 Mar;
23(1):124-133.e7.
PMID: 38492905
Background & Aims: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab...
3.
Rentsch C, Ward M, Luber R, Taylor K, Gibson D, Headon B, et al.
Ther Drug Monit
. 2022 Sep;
45(3):383-391.
PMID: 36174193
Background: Therapeutic monitoring of infliximab is limited by the time lag between drug-level measurement and dose adjustment, along with the cost of dose escalation. Strategies for dose reduction in stable...
4.
Liu Z, Julsgaard M, Zhu X, Martin J, Barclay M, Cranswick N, et al.
J Crohns Colitis
. 2022 Jul;
16(12):1835-1844.
PMID: 35779236
Background And Aims: For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is...
5.
Flanagan E, Prentice R, Wright E, Gibson P, Ross A, Begun J, et al.
Aliment Pharmacol Ther
. 2021 Dec;
55(6):700-704.
PMID: 34907546
Background: Ustekinumab is increasingly used in pregnant women with inflammatory bowel disease (IBD). Existing safety data are reassuring, but the stability of ustekinumab levels in pregnancy, degree of transfer to...
6.
Ardalan Z, Friedman A, Con D, Chandran S, Gibson D, Pham A, et al.
J Crohns Colitis
. 2021 Jul;
16(1):79-90.
PMID: 34302729
Background And Aims: In symptomatic patients with ileoanal pouches, pouchoscopy is needed for accurate diagnosis but is invasive. We aimed to assess the utility of non-invasive gastrointestinal ultrasound and faecal...
7.
Ward M, Rosella O, Rosella G, Martin C, Gibson P
Ther Drug Monit
. 2021 Jan;
43(5):692-695.
PMID: 33492105
Background: The optimal use of infliximab depends on the measurement of trough levels with subsequent appropriate dose adjustment. With the introduction of biosimilars, it is important to demonstrate that the...
8.
Flanagan E, Gibson P, Wright E, Moore G, Sparrow M, Connell W, et al.
Aliment Pharmacol Ther
. 2020 Sep;
52(10):1551-1562.
PMID: 32981127
Background: The impact of pregnancy on levels of biologic agents in patients with IBD is undefined and time to elimination in vedolizumab-exposed infants is unknown. Aims: To determine the effect...
9.
Flanagan E, Gibson P, Begun J, Ghaly S, Garg M, Andrews J, et al.
Aliment Pharmacol Ther
. 2018 Nov;
48(11-12):1328-1330.
PMID: 30488628
No abstract available.
10.
Beswick L, Rosella O, Rosella G, Headon B, Sparrow M, Gibson P, et al.
J Crohns Colitis
. 2017 Nov;
12(3):289-297.
PMID: 29121178
Background: The outcomes of acute severe ulcerative colitis [ASUC] appear to be dependent on early intervention with the first and/or further infliximab [IFX] doses, although parameters to guide decision-making remain...